ASCO Annual Meeting

Patient Advocacy at ASCO 2022

July 22nd 2022, 5:00pm

Article

This year, I returned to the American Society of Clinical Oncology meeting, where I heard about the latest advancements in cancer care, as well as met with fellow patients and advocates.

Time-Limited Venclexta Regimens Outperform Chemoimmunotherapy in CLL

June 13th 2022, 9:00pm

Article

Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Brukinsa Continues to Outperform Imbruvica for MYD88-Mutant Waldenström Macroglobulinemia

June 10th 2022, 9:00pm

Article

Brukinsa, which was approved in September 2021, resulted in better ouctomes for certain patients with with Waldenström macroglobulinemia, according to the ASPEN clinical trial.

Addition of Stem Cell Transplant Boosts Outcomes for Common Myeloma Regimen

June 10th 2022, 7:00pm

Article

Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant.

Pre- and Post-Surgical Jakafi Plus Chemo Shows Potential in Advanced Ovarian Cancer

June 9th 2022, 7:00pm

Article

The use of Jakafi plus chemotherapy shows promise in the pre- and post-surgical treatment settings for patients with stage 3 and 4 ovarian cancer, warranting further study of the combination.

Keytruda Demonstrates Significant Improvement for Some Patients with Melanoma

June 9th 2022, 3:00pm

Article

Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo.

Durable Responses Continue with Keytruda Plus Chemoradiation in Previously Untreated Non-Small Cell Lung Cancer

June 8th 2022, 9:00pm

Article

After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.

Jemperli Eliminated All Signs of Rectal Cancer in Small Clinical Trial, Warranting Further Research

June 8th 2022, 7:00pm

Article

One-hundred percent of patients with stage 2/3 mismatch repair-deficient rectal cancer had their disease disappear after treatment with Jermperli, though more research and longer follow-up is needed.

Exkivity Delivers Minimal Benefit to Patients with Non-Small Cell Lung Cancer and Brain Metastases

June 8th 2022, 3:00pm

Article

Although ineffective in patients with non-small cell lung cancer and brain metastases at diagnosis, treatment with Exkivity may benefit patients with EGFR exon 20 insertion-positive metastatic disease.

Ifosfamide Induces ‘Subtle’ Survival Improvement Over Hycamtin-Cyclophosphamide Combo in Ewing Sarcoma

June 7th 2022, 9:00pm

Article

The use of the chemotherapy ifosfamide was associated with small improvements in survival outcomes in a group of patients with relapsed/refractory Ewing sarcoma, a rare type of bone or soft tissue cancer.